Merck Signals Strategic Shift with Plan to Separate Cancer Business as Keytruda Patent Cliff Looms

Pharmaceutical giant Merck is reportedly preparing to establish a separate cancer business unit to navigate the upcoming loss of patent protection for its flagship immunotherapy, Keytruda. The move reflects a broader industry trend of corporate restructuring to isolate high-growth assets from legacy revenue risks.

Kwame Osei

February 23, 2026686 views

Related Stories

Finance

Stellantis Records First Annual Loss in History Following 20 Billion Euro EV Writedown

1d ago

Finance

Imperial Petroleum Accelerates Fleet Expansion as Valuation Multiples Lag Behind Earnings

1d ago

Finance

Syngenta Prepares $10 Billion Hong Kong IPO for Second Quarter Launch

1d ago

Finance

Uber and Lyft Shares Surge as Trump Administration Scraps Independent Contractor Rule

1d ago

Comments (1)

Sign in to leave a comment.

Grace Coleman4d ago

It is fascinating to see

00

Reply